Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. Matthews DA, et al. Among authors: zhou r. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7. doi: 10.1073/pnas.96.20.11000. Proc Natl Acad Sci U S A. 1999. PMID: 10500114 Free PMC article.
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST. Dragovich PS, et al. Among authors: zhou r. Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8. doi: 10.1016/s0960-894x(02)00008-2. Bioorg Med Chem Lett. 2002. PMID: 11858991
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST. Dragovich PS, et al. Among authors: zhou r. J Med Chem. 2002 Apr 11;45(8):1607-23. doi: 10.1021/jm010469k. J Med Chem. 2002. PMID: 11931615
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA. Dragovich PS, et al. Among authors: zhou r. J Med Chem. 2003 Oct 9;46(21):4572-85. doi: 10.1021/jm030166l. J Med Chem. 2003. PMID: 14521419
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST. Dragovich PS, et al. Among authors: zhou r. J Med Chem. 1998 Jul 16;41(15):2806-18. doi: 10.1021/jm980068d. J Med Chem. 1998. PMID: 9667970
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST. Dragovich PS, et al. Among authors: zhou r. J Med Chem. 1998 Jul 16;41(15):2819-34. doi: 10.1021/jm9800696. J Med Chem. 1998. PMID: 9667971
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW 3rd, Ferre RA, Harr JE, Kosa MB, Worland ST. Dragovich PS, et al. Among authors: zhou r. J Med Chem. 1999 Apr 8;42(7):1213-24. doi: 10.1021/jm9805384. J Med Chem. 1999. PMID: 10197965
Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.
Dragovich PS, Webber SE, Prins TJ, Zhou R, Marakovits JT, Tikhe JG, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Brown EL, Binford SL, Meador JW 3rd, Ferre RA, Worland ST. Dragovich PS, et al. Among authors: zhou r. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2189-94. doi: 10.1016/s0960-894x(99)00368-6. Bioorg Med Chem Lett. 1999. PMID: 10465543
8,835 results